Mark Ball, MD, FACS

Urologic Oncologist at NCI | Assoc Prof & Fellowship APD | #kidneycancer #pheo surgery & translational genomics 🧬 Views mine

[Mark Ball, MD, FACS @markballmd]

So great to meet all of the residents at @AmerUrological #AUAFundamentals today and to discuss #KidneyCancer.

My @michaelpollan inspired approach to kidney tumors:

[Mark Ball, MD, FACS @markballmd]

@UrolOncol @SUO_YUO @UroOnc Great work, @alirezaghoreifi

[Urologic Oncology @UrolOncol]

Thank you to our 3,000+ followers for engaging with Urologic Oncology: Seminars and Original Investigations. Your support helps amplify important work in urologic cancer research, education, and collaboration.
@markballmd @SUO_YUO @UroOnc

[Urologic Oncology @UrolOncol]

🔥The April 2026 issue of 'Urologic Oncology: Seminars and Original Investigations' is now available.

Click here to stay on top of urologic oncology ▶️ https://t.co/rmql0AeTZg

#NowOnline #UroSoMe #MedTwitt

[Mark Ball, MD, FACS @markballmd]

@SPuro88 @w_witthaus Needs one more nipple on the tip of the scope.

[Mark Ball, MD, FACS @markballmd]

NCI Urologic Oncolgy Branch is still accepting @SUO_YUO fellowship applications - interviews April 13, 14, 20. DM or email [email protected] for more information.

[UroToday.com @urotoday]

Unraveling smooth muscle-rich #RenalCellCarcinoma: Clinical, oncological, genetic, and pathological insights. #AuthorCommentary

Smooth muscle–rich #RCC is a rare but distinct entity. In the largest cohort to date, smrRCC showed frequent bilateral multifocal disease, unique genetic features, and rare metastatic potential—highlighting the need for genetic testing, surveillance, and nephron-sparing care. #ReadMore on UroToday > https://t.co/f61I4gzWnS @RubenBlachmanMD @MillanBraden @markballmd @theNCI @urogoldjournal

[Mark Ball, MD, FACS @markballmd]

I’ve spent my entire professional career as a cancer surgeon fighting cancer in the OR.

This spring, I’m taking that fight to the mats. 🥋🎗️

Proud to compete in Tap Cancer Out Baltimore on May 9, 2026, representing Culture of Jiu Jitsu Academy.

I'm asking for your help. Please donate below and support the fight:
https://t.co/Yjl2niIGBG

#TapCancerOut #RollToEndCancer #BJJForACause

[Mark Ball, MD, FACS @markballmd]

A familiar face returns, wiser in years and rich in scholarship. Welcome back @PGomellaMD, to UOB grand rounds on Genetics of Prostate Cancer.

[UroToday.com @urotoday]

Unraveling smooth muscle-rich #RenalCellCarcinoma: Clinical, oncological, genetic, and pathological insights. #AuthorCommentary

Smooth muscle–rich #RCC is a rare but distinct entity. In the largest cohort to date, smrRCC showed frequent bilateral multifocal disease, unique genetic features, and rare metastatic potential—highlighting the need for genetic testing, surveillance, and nephron-sparing care. #ReadMore on UroToday > https://t.co/f61I4gzWnS @RubenBlachmanMD @MillanBraden @markballmd @theNCI @urogoldjournal

[Urologic Oncology @UrolOncol]

Congratulations to @UrolOncol 2025 Best Reviewers!
#SUO2025 @SUO_YUO @UroOnc
@VikramNarayan @LauraBukavinaMD @therealUroJET @TaylorGoodstein @rezanab @PCuroMD @abetakashige

[Urologic Oncology @UrolOncol]

The editorial team of Urologic Oncology extends its sincere appreciation to our peer reviewers who have completed over 100 manuscript reviews. Their dedication of time, depth of expertise, and thoughtful insight strengthen the journal’s quality and help advance the field.

[Mark Ball, MD, FACS @markballmd]

What a treat to chat with these three kidney cancer thought leaders.

[BackTable Urology @_backtableUro]

Kidney cancer management is evolving - how are experts adapting? Dr. Brandon Manley, @Raquib_Hannan, & @DrRanaMcKay join @markballmd for a multidisciplinary discussion on kidney cancer care @_backtableONC #URO263

This episode is supported by: @ferring

https://t.co/w00XyU7es5

[BackTable Tumor Board @_backtableONC]

Kidney cancer management is evolving. How are experts adapting?

In this installment of BackTable Tumor Board, Dr. Brandon Manley, Dr. Raquibul Hannan, and Dr. Rana McKay join guest host Dr. Mark Ball to share their multidisciplinary perspectives on challenging, real-world kidney cancer cases.

This podcast is supported by: Ferring Pharmaceuticals

Watch the episode here: https://t.co/3VkXRmEhn7

#ONC23 #kidneycancer #oncology #urology

[Ali Sheikhy, MD @AliSheikhyMD]

MRI features can distinguish benign from malignant HLRCC-associated renal cysts. Our model could spare >50% of patients with benign cysts from unnecessary surgery.

Huge thanks to my PI @aamalayeri and our amazing team @aryanzg @NIHClinicalCntr !

https://t.co/cRnMnrCdmI

[Mark Ball, MD, FACS @markballmd]

@LauraBukavinaMD @uretericbud Both funny and unfunny until someone hears the punch line

[Mark Ball, MD, FACS @markballmd]

Quantum surgery

[Urologic Oncology @UrolOncol]

📢Published in the September issue of @UrolOncol

Feasibility and perioperative outcomes of re-operative retroperitoneal robotic partial nephrectomy

Click here to read the article▶️https://t.co/vAqxn0qlj5

#UroSoMe #MedTwitter #kidneycancer

[Mark Ball, MD, FACS @markballmd]

@aamalayeri @NIHClinicalCntr @NIH We miss you already. Thank you for willingness to always pick up the phone to discuss a case, your partnership in research and your friendship.